Researchers from Mass General Brigham and the Broad Institute of MIT and Harvard have identified genetic modifications that can improve the efficacy of chimeric antigen receptor (CAR)-T cell treatment — an immunotherapy that uses modified patient T cells to target cancer. The study used CRISPR screening to pinpoint genes that influenced T cell function and survival in culture and in a preclinical model of multiple myeloma. Their results and technique, published in Nature, could lead to T cell-based immunotherapies for cancer.

Researchers from USC and Duke report that the persistent “know-do gap” — where clinicians know guidelines but practice differently — is the primary driver of antibiotic overprescribing for pediatric diarrhea in India’s private sector, not lack of knowledge, point-of-sale profits, or stockouts of clinically recommended treatments such as oral rehydration salts (ORS).